Publications by authors named "Susana Clemente"
Cardiopulmonary exercise testing (CPET) provides a noninvasive and integrated assessment of the response of the respiratory, cardiovascular, and musculoskeletal systems to exercise. This information improves the diagnosis, risk stratification, and therapeutic management of several clinical conditions. Additionally, CPET is the gold standard test for cardiorespiratory fitness quantification and exercise prescription, both in patients with cardiopulmonary disease undergoing cardiac or pulmonary rehabilitation programs and in healthy individuals, such as high-level athletes.
View Article and Find Full Text PDFArticle Synopsis
- This study focuses on how gene expression changes may affect pediatric patients with inflammatory bowel diseases (IBDs) in their response to anti-TNF treatments like infliximab and adalimumab.
- Researchers analyzed blood samples from 24 patients to identify genes that could predict early treatment responses, discovering 102 differentially expressed genes.
- Key findings included four validated genes (CEACAM8, LCN2, LTF2, and PRTN3) that showed increased expression in responders, highlighting their potential role in treatment effectiveness and involvement in immune responses.
Article Synopsis
- * A total of 340 pediatric patients treated with infliximab or adalimumab were genotyped for 9 specific genetic variants, revealing that certain variants are linked to poorer long-term treatment outcomes.
- * Identifying these genetic markers could help tailor anti-TNF therapy for children, allowing healthcare providers to better predict which patients are likely to benefit in the long run, pending further validation.
Article Synopsis
- The study investigates the genetic variants rs2395185 and rs2097432 in HLA genes and their effect on the long-term efficacy of anti-TNF treatments in children with inflammatory bowel disease (IBD).
- Researchers conducted an analysis on 340 pediatric IBD patients from Spanish hospitals, using statistical methods to assess the impact of these genetic polymorphisms on treatment outcomes.
- Results showed that specific alleles (homozygous G for rs2395185 and C for rs2097432) were linked to a reduced long-term response to anti-TNF drugs, highlighting a difference in response between children and adults with Crohn's disease treated with infliximab.
The PERSEIDS study aimed to estimate incidence/prevalence of interstitial lung diseases (ILDs), fibrosing interstitial lung diseases (F-ILDs), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD (SSc-ILD), other non-IPF F-ILDs and their progressive-fibrosing (PF) forms in six European countries, as current data are scarce. This retrospective, two-phase study used aggregate data (2014-2018). In Phase 1, incident/prevalent cases of ILDs above were identified from clinical databases through an algorithm based on codes/keywords, and incidence/prevalence was estimated.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed gene expression profiles from blood samples of 12 patients (6 responders and 6 non-responders) before and after two weeks of anti-TNF treatment using advanced RNA sequencing techniques.
- * They found specific genes that were significantly overexpressed in non-responders, indicating potential biomarkers for early response to anti-TNF therapy in pediatric IBD patients.
Objectives: Inflammatory bowel disease (IBD) is more complex in children and they will have to live with the disease for much longer. For this reason, it is necessary to optimize treatment. The polymorphisms associated with the response to anti-tumor necrosis factor (TNF) drugs in adults with IBD have not been analyzed in children.
View Article and Find Full Text PDFAims: Identifying DNA variants associated with trough serum anti-tumour necrosis factor (TNF) levels could predict response to treatment in inflammatory bowel disease (IBD). To date, no specific studies have been performed in children. The aim of this study was to identify genetic variants associated with trough serum anti-TNF levels and whether these variants are differential markers for infliximab and adalimumab.
View Article and Find Full Text PDFIsolated Pulmonary Mucormycosis in an immunocompetent patient.
Rev Port Cir Cardiotorac Vasc
October 2019
Mucormycosis is a life-threatening fungal infection that occurs mainly in immunocompromised patients. Its occurrence isolated in the lung rare and carries a high mortality risk if untreated. We report the case of a 76-year old male immunocompetent patient, under treatment for pulmonary tuberculosis, admitted to the emergency department with hemoptysis.
View Article and Find Full Text PDFhttp://ow.ly/yYq230dDqcd.
View Article and Find Full Text PDFThe authors report a case of a primary pulmonary epithelioid haemangioendothelioma (EHE) in a 51 year-old man, a mechanic, who complained of a dry cough followed by constitutional symptoms and dyspnoea. Patient underwent a series of diagnostic exams including surgical biopsy and pulmonary tuberculosis was diagnosed. He was prescribed tuberculosis drugs for three weeks.
View Article and Find Full Text PDF